Last reviewed · How we verify
NCT04359121
COVID-19 and the Developement of Phobic Fears of Disease
trial testing Questionnaires for specific phobia in COVID19 in 600 participants. Status unknown.
15 November 2023
Quick facts
| Lead sponsor | Medical University of Graz |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 15 December 2020 |
| Primary completion | 15 November 2023 |
| Estimated completion | 15 November 2023 |
| Sites | 1 location across Austria |
Drugs / interventions tested
- Questionnaires for specific phobia
Conditions studied
- COVID19 — all drugs for COVID19 →
Sponsor
Medical University of Graz
Who can join
Adults 18 to 90, any sex, with COVID19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A lot of people suffer from phobias. Phobias concerning certain diseases are not rare. This study will examine whether the COVID-19 (Coronavirus Disease) crisis was able to rise phobias in people and if those with preexisting phobias or fears were more likely to develop a phobia concerning COVID. It will look at different subtypes - physicians, medical staff, general public (not medically affiliated) and patients with psychiatric disorders.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A biopsychosocial model of severe fear of COVID-19.
Nürnberger P, von Lewinski D, Rothenhäusler HB, Braun C, et al · · 2022 · cited 9× · PMID 35226661 · DOI 10.1371/journal.pone.0264357
Verify or expand the search:
- PubMed search for NCT04359121
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID19
Currently open trials in the same condition.
- NCT07337382 — The Optimising Isolation, Quarantine and Distancing Study for COVID-19 · active not recruiting
- NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting
- NCT04367883 — Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection · recruiting
Other Medical University of Graz trials
Trials by the same sponsor.
- NCT07498244 — Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) Patients · recruiting
- NCT07492823 — Clinical Applicability of Liquid Biopsy in Chondrosarcoma · not yet recruiting
- NCT07297615 — 3D Liver Volumetry · NA · not yet recruiting
- NCT07588282 — The Effect of Psychoeducational Diagnosis Communication on Perception of Illness, Satisfaction, and Behavioral Intention · NA · recruiting
- NCT07376096 — Liquid Biopsy in Germ Cell Tumors · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04359121 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of Graz
- Last refreshed: 11 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04359121.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing